ASCO: Olaparib Beats Placebo for BRCA-Related Pancreatic Cancer

TUESDAY, June 4, 2019 -- Maintenance therapy with olaparib is associated with improved progression-free survival in metastatic pancreatic cancer patients with a germline BRCA1 and/or BRCA2 mutation (gBRCAm), according to a study presented at the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news